Insmed (INSM) Depreciation & Amortization (CF) (2010 - 2014)
Insmed (INSM) posted quarterly Depreciation & Amortization (CF) of $2.9 million for Q1 2026, up 55.82% year-over-year from $1.9 million in Q1 2025, and down 17.93% quarter-over-quarter from $3.6 million in Q4 2025.
Powered by 
Analysis
Insmed (INSM) Depreciation & Amortization (CF) (2010 - 2014) Analysis & Trends
Insmed's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 55.82% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $11.5 million (up 81.91% YoY), while the FY2025 annual figure was $10.4 million, up 73.33% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $2.9 million, down from $3.6 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $3.6 million in Q4 2025, with the low at $851000.0 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $1.5 million (2023), against an average of $1.8 million.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) sank 61.97% in 2022, then jumped 135.66% in 2025.
- Insmed's Depreciation & Amortization (CF) stood at $2.2 million in 2022, then tumbled by 32.43% to $1.5 million in 2023, then climbed by 2.85% to $1.5 million in 2024, then surged by 135.66% to $3.6 million in 2025, then slipped by 17.93% to $2.9 million in 2026.
- Business Quant data shows INSM's Depreciation & Amortization (CF) at $2.9 million in Q1 2026, $3.6 million in Q4 2025, and $2.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 26.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2014 | 376,000.00 |
| Sep 30, 2014 | 355,000.00 |
| Jun 30, 2014 | 175,000.00 |
| Mar 31, 2014 | 167,000.00 |
| Dec 31, 2013 | 205,000.00 |
| Sep 30, 2013 | 171,000.00 |
| Jun 30, 2013 | 156,000.00 |
| Mar 31, 2013 | 148,000.00 |
| Dec 31, 2012 | 149,000.00 |
| Sep 30, 2012 | 138,000.00 |
| Jun 30, 2012 | 138,000.00 |
| Mar 31, 2012 | 136,000.00 |
| Dec 31, 2011 | 110,000.00 |
| Sep 30, 2011 | 79,000.00 |
| Jun 30, 2011 | 79,000.00 |
| Mar 31, 2011 | 75,000.00 |
| Dec 31, 2010 | 29,000.00 |